Retinitis Pigmentosa: Understanding Inherited Vision Loss

In autosomal dominant RP, only one copy of the mutated gene is needed to cause the condition. A child of an affected parent has roughly a one in two chance of inheriting the mutation. This form accounts for a meaningful portion of all RP cases.

Autosomal recessive RP requires that both parents carry a copy of the mutated gene. Each child then has a one in four chance of being affected. Parents who carry a single copy typically do not have symptoms themselves. In families where parents share a blood relationship, the likelihood that both carry the same recessive mutation is higher.

X-linked RP is carried on the X chromosome and primarily affects males. Females who carry the mutation may have mild symptoms or none at all. X-linked RP tends to progress more quickly, particularly in males, compared to other inheritance patterns.

Some people with RP also have conditions affecting other body systems. Usher syndrome, the most common syndromic form, causes both RP-related vision loss and hearing loss. Bardet-Biedl syndrome involves RP along with other systemic features. Sporadic RP cases with no known family history can also occur, sometimes due to a new gene mutation. Genetic testing can clarify whether RP is part of a broader syndrome.

Luxturna (voretigene neparvovec) is currently the only FDA-approved gene therapy for an inherited retinal disease. It is designed for patients whose RP (or a related condition called Leber congenital amaurosis) is caused by mutations in both copies of the RPE65 gene. This accounts for a small percentage of all RP cases. The therapy delivers a working copy of the gene directly into the retina through a surgical procedure, and clinical studies have shown meaningful improvements in the ability to navigate in low light.

Luxturna is not a treatment for all types of RP. Genetic testing is required to determine whether a patient carries the RPE65 mutation and may be eligible. Patients who may qualify are referred to the appropriate surgical retina specialist for evaluation.

Some research has suggested that vitamin A palmitate may slow retinal degeneration in certain RP patients. However, high-dose vitamin A can be harmful to the liver and is not appropriate for everyone. Pregnant women or those planning pregnancy should not take high-dose vitamin A. Any supplementation should only be started under the direct guidance of a physician or retina specialist.

People with RP are more likely to develop additional eye conditions that can further affect their vision. Cataracts, which involve clouding of the eye's natural lens, are common in RP patients and can be addressed with surgery when appropriate. Cystoid macular edema, a type of swelling in the central retina, may also occur and can sometimes be managed with medications. Treating these complications when they arise can help preserve functional vision for longer.

Low vision rehabilitation helps people with RP make the most of their remaining sight. Tools such as magnifying glasses, telescopic lenses, high-contrast screen settings, and text-to-speech software can assist with daily tasks. Orientation and mobility training helps individuals move safely and confidently through their environment. A retina specialist can refer patients to low vision specialists whose services are tailored to their specific level of vision.

Yes, it is possible to identify signs of RP before noticeable vision loss occurs. Electroretinography can detect reduced electrical activity in the retina at an early stage, and genetic testing can identify a mutation in at-risk family members who are still symptom-free. If you have a family member who has been diagnosed with RP, speaking with a retina specialist about proactive screening is a reasonable next step, even if your vision currently seems fine.

Luxturna is the only FDA-approved gene therapy for inherited retinal disease as of 2026, and it applies only to patients with RPE65 gene mutations, which is a small subset of all RP cases. For the majority of patients, treatment focuses on managing complications, supporting remaining vision, and monitoring for changes. Additional gene therapies targeting other mutations are in clinical trials, which is why identifying your specific mutation through genetic testing is an important step, even if it does not immediately open a treatment door.

The risk to your children depends on which gene is involved and how it is inherited. In dominant forms, the risk is roughly one in two per child. In recessive forms, both parents must carry the mutation, and each child then has a one in four chance of being affected. Genetic counseling provides personalized risk information based on your specific test results and family situation, which is far more reliable than general estimates. This is especially helpful when planning a family after a diagnosis has been made.

There is no established recommendation to completely avoid light, but wearing UV-protective sunglasses outdoors is generally advised to reduce any additional stress on an already vulnerable retina. Extreme sensitivity to bright light, called photophobia, is a symptom some RP patients experience, and adjusting lighting in daily environments can help manage comfort. If you notice that bright light is significantly affecting your vision or daily functioning, discuss this with your retina specialist, as it can inform how your condition is being monitored.

These are known complications that can develop alongside RP, and they are treatable. Cataracts can be surgically removed when they begin to interfere meaningfully with vision. Macular edema, a type of retinal swelling, can sometimes be managed with prescription eye drops or other medications. Addressing these complications often provides a noticeable improvement in functional vision, even when the underlying RP cannot be reversed. Regular monitoring is the best way to catch these issues early.

This is a situation many RP patients face, and it does not mean there is nothing to be done. Monitoring your condition carefully, managing complications, and supporting your remaining vision with low vision tools are all meaningful actions. Documenting your genetic mutation now also positions you to be considered for clinical trials and new therapies as they emerge. The field is moving forward quickly, and staying connected with a knowledgeable retina specialist is the best way to remain informed as options develop.